Table 1

Clinical characteristics of the 143 patients entering the study*

Age > 60 y (n = 40)Age < 60 y (n = 103)Total (n = 143)P
Sex     
    Male 21 59 80 NS 
    Female 19 44 63  
WBC     
    Less than 50 × 109/L 37 73 110 NS 
    50-100 × 109/L 21 22  
    More than 100 × 109/L 11  
FAB     
    M0 11 13 NS 
    M1 21 30  
    M2 13 31 44  
    M4 13 22  
    M5 26 31  
    M6  
FLT3 status (n = 129)     
    Wild-type 31 79 110 NS 
    ITD 14 19  
NPM1 status (n = 135)     
    Wild-type 27 68 95 NS 
    Mutated 13 27 40  
Cytogenetics    .014 
    Good-risk 20 22  
    Intermediate-risk 24 32  
    Normal karyotype 26 57 83  
    Poor-risk  
Age > 60 y (n = 40)Age < 60 y (n = 103)Total (n = 143)P
Sex     
    Male 21 59 80 NS 
    Female 19 44 63  
WBC     
    Less than 50 × 109/L 37 73 110 NS 
    50-100 × 109/L 21 22  
    More than 100 × 109/L 11  
FAB     
    M0 11 13 NS 
    M1 21 30  
    M2 13 31 44  
    M4 13 22  
    M5 26 31  
    M6  
FLT3 status (n = 129)     
    Wild-type 31 79 110 NS 
    ITD 14 19  
NPM1 status (n = 135)     
    Wild-type 27 68 95 NS 
    Mutated 13 27 40  
Cytogenetics    .014 
    Good-risk 20 22  
    Intermediate-risk 24 32  
    Normal karyotype 26 57 83  
    Poor-risk  
*

Patients were stratified according to refined MRC classification of cytogenetic risk, as follows: “favorable” risk, cases with t(8;21), t(15;17), or inv(16)/t(16;16); “adverse” risk, cases with complex cytogenetic changes (> 3 unrelated abnormalities), −5, add(5q)/del(5q), −7/add(7q), t(6;11), t(10;11), t(9;22), −17, abn(17p) with other changes, 3q abnormalities excluding t(3;5), inv(3)/t(3;3); and “intermediate” risk, cases with normal karyotype and other noncomplex.

WBC indicates white blood cell; FAB, French-American-British; and NS, not significant.

Close Modal

or Create an Account

Close Modal
Close Modal